165 related articles for article (PubMed ID: 31832851)
1. Sorafenib may enhance antitumour efficacy in hepatocellular carcinoma patients by modulating the proportions and functions of natural killer cells.
Hu J; Wang E; Liu L; Wang Q; Xia D; Bai W; Tie J; Li X; Yuan J; Yang S; Jiang D; Shi J; Sun Y; Wang J; Zhang C; Niu J; Li K; He C; Guo W; Lv Y; Chen H; Yuan X; Yu T; Wang Z; Luo B; Han N; Zhu Y; Yin Z; Fan D; Zhang Z; Yang K; Han G
Invest New Drugs; 2020 Oct; 38(5):1247-1256. PubMed ID: 31832851
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2.
Li C; Wei S; Xu X; Jiang Y; Xue L; Jiang P; Wang J
Int Immunopharmacol; 2019 Nov; 76():105855. PubMed ID: 31472321
[TBL] [Abstract][Full Text] [Related]
3. [Percentages and functions of natural killer cell subsets in peripheral blood of patients with severe aplastic anemia].
Li ZS; Shao ZH; Fu R; Wang J; Li LJ; Zhang T; Wang HQ; Wu YH; Ruan EB; Song J; Qu W; Liu H; Xing LM; Wang XM; Liang Y; Guan J; Wang GJ
Zhonghua Yi Xue Za Zhi; 2011 Apr; 91(16):1084-7. PubMed ID: 21609587
[TBL] [Abstract][Full Text] [Related]
4. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
[TBL] [Abstract][Full Text] [Related]
5. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles.
Wu M; Mei F; Liu W; Jiang J
Biomed Pharmacother; 2020 Jan; 121():109637. PubMed ID: 31810126
[TBL] [Abstract][Full Text] [Related]
7. CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer.
Gogali F; Paterakis G; Rassidakis GZ; Liakou CI; Liapi C
Thyroid; 2013 Dec; 23(12):1561-8. PubMed ID: 23721357
[TBL] [Abstract][Full Text] [Related]
8. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
[TBL] [Abstract][Full Text] [Related]
9. [Characteristics of peripheral NK cells in hepatocellular carcinoma patients].
Zhou L; Cai L; Zhang Z; Yang YP; Wang FS
Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):136-9. PubMed ID: 20196954
[TBL] [Abstract][Full Text] [Related]
10. Diminished absolute counts of CD56dim and CD56bright natural killer cells in peripheral blood from Egyptian patients with hepatocellular carcinoma.
Fathy A; Eldin MM; Metwally L; Eida M; Abdel-Rehim M
Egypt J Immunol; 2009; 16(2):17-25. PubMed ID: 22059350
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Sprinzl MF; Reisinger F; Puschnik A; Ringelhan M; Ackermann K; Hartmann D; Schiemann M; Weinmann A; Galle PR; Schuchmann M; Friess H; Otto G; Heikenwalder M; Protzer U
Hepatology; 2013 Jun; 57(6):2358-68. PubMed ID: 23424039
[TBL] [Abstract][Full Text] [Related]
12. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Huth TK; Staines D; Marshall-Gradisnik S
J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
[TBL] [Abstract][Full Text] [Related]
13. CD56
Wang H; Zeng Y; Zhang M; Ma H; Xu B; Jiang H; Wang J; Li G
Hum Immunol; 2019 Oct; 80(10):871-877. PubMed ID: 31326139
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.
Kalathil SG; Hutson A; Barbi J; Iyer R; Thanavala Y
JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391334
[TBL] [Abstract][Full Text] [Related]
15. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
Goyal L; Zheng H; Abrams TA; Miksad R; Bullock AJ; Allen JN; Yurgelun MB; Clark JW; Kambadakone A; Muzikansky A; Knowles M; Galway A; Afflitto AJ; Dinicola CF; Regan E; Hato T; Mamessier E; Shigeta K; Jain RK; Duda DG; Zhu AX
Clin Cancer Res; 2019 Jan; 25(1):80-89. PubMed ID: 30190369
[TBL] [Abstract][Full Text] [Related]
16. Circulating NK cells and their subsets in Behçet's disease.
Hasan MS; Ryan PL; Bergmeier LA; Fortune F
Clin Exp Immunol; 2017 May; 188(2):311-322. PubMed ID: 28170096
[TBL] [Abstract][Full Text] [Related]
17. Human CD56
Amand M; Iserentant G; Poli A; Sleiman M; Fievez V; Sanchez IP; Sauvageot N; Michel T; Aouali N; Janji B; Trujillo-Vargas CM; Seguin-Devaux C; Zimmer J
Front Immunol; 2017; 8():699. PubMed ID: 28674534
[TBL] [Abstract][Full Text] [Related]
18. Early Cytomegalovirus Reactivation and Expansion of CD56
Jang JE; Hwang DY; Chung H; Kim SJ; Eom JI; Jeung HK; Song J; Kim JS; Cheong JW; Min YH
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2070-2078. PubMed ID: 31212079
[TBL] [Abstract][Full Text] [Related]
19. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
20. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
